Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 4
2014 3
2015 4
2016 1
2017 1
2018 1
2019 5
2020 6
2021 4
2022 2
2023 6
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L, Guardascione M, D'Andrea M, Favaretto A, Puglisi F, Swen JJ, Guchelaar HJ, Toffoli G, Cecchin E. Roncato R, et al. Among authors: foltran l. JAMA Netw Open. 2024 Dec 2;7(12):e2449441. doi: 10.1001/jamanetworkopen.2024.49441. JAMA Netw Open. 2024. PMID: 39641926 Free PMC article. Clinical Trial.
Precision oncology in biliary tract cancer: the emerging role of liquid biopsy.
de Scordilli M, Bortolot M, Torresan S, Noto C, Rota S, Di Nardo P, Fumagalli A, Guardascione M, Ongaro E, Foltran L, Puglisi F. de Scordilli M, et al. Among authors: foltran l. ESMO Open. 2025 May;10(5):105079. doi: 10.1016/j.esmoop.2025.105079. Epub 2025 Apr 30. ESMO Open. 2025. PMID: 40311184 Free PMC article. Review.
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial.
Nasca V, Bergamo F, Foltran L, Antonuzzo L, Bencardino K, Dell'Aquila E, Corallo S, Spallanzani A, Brunetti O, Spada D, Tamberi S, Cella CA, Avallone A, Fornaro L, Di Donato S, Strippoli A, Puccini A, Tamburini E, Palermo F, Morano F, Pietrantonio F, Raimondi A. Nasca V, et al. Among authors: foltran l. BMC Cancer. 2025 Apr 8;25(1):633. doi: 10.1186/s12885-025-14063-6. BMC Cancer. 2025. PMID: 40200187 Free PMC article.
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
Michelotti A, de Scordilli M, Palmero L, Guardascione M, Masala M, Roncato R, Foltran L, Ongaro E, Puglisi F. Michelotti A, et al. Among authors: foltran l. Cells. 2021 Aug 9;10(8):2034. doi: 10.3390/cells10082034. Cells. 2021. PMID: 34440803 Free PMC article. Review.
Liquid biopsy in colorectal cancer: Onward and upward.
Torresan S, de Scordilli M, Bortolot M, Di Nardo P, Foltran L, Fumagalli A, Guardascione M, Ongaro E, Puglisi F. Torresan S, et al. Among authors: foltran l. Crit Rev Oncol Hematol. 2024 Feb;194:104242. doi: 10.1016/j.critrevonc.2023.104242. Epub 2023 Dec 20. Crit Rev Oncol Hematol. 2024. PMID: 38128627 Review.
Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives.
de Scordilli M, Michelotti A, Zara D, Palmero L, Alberti M, Noto C, Totaro F, Foltran L, Guardascione M, Iacono D, Ongaro E, Fasola G, Puglisi F. de Scordilli M, et al. Among authors: foltran l. Crit Rev Oncol Hematol. 2023 Jun;186:104013. doi: 10.1016/j.critrevonc.2023.104013. Epub 2023 Apr 26. Crit Rev Oncol Hematol. 2023. PMID: 37116817 Review.
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA).
Di Nardo P, Basile D, Siciliano A, Pelizzari G, Corvaja C, Buriolla S, Ongaro E, Maria Grazia D, Garattini SK, Foltran L, Guardascione M, Casagrande M, Buonadonna A, Prantera T, Aprile G, Puglisi F. Di Nardo P, et al. Among authors: foltran l. Dig Liver Dis. 2024 May;56(5):786-794. doi: 10.1016/j.dld.2023.07.013. Epub 2023 Aug 14. Dig Liver Dis. 2024. PMID: 37586908
41 results